To validate our cell fusion method, we began by fusing SK-MEL-2 melanoma cells genome-edited to express clathrin-RFP (Clta-RFP) or dynamin2-GFP (Dnm2-GFP) from their endogenous genomic loci (Doyon et al., 2011). The gene discussed is DNM2; the disease is melanoma.